|
2024
|
Invention
|
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory ... |
|
|
Invention
|
Antibody-drug conjugates and uses thereof.
The present invention relates to therapeutic immunoco... |
|
|
Invention
|
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity.... |
|
2023
|
Invention
|
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan ... |
|
|
G/S
|
Providing health and medical information about oncological disorders and their diagnosis, prevent... |
|
|
G/S
|
Providing health and medical information about oncological
disorders and their diagnosis, preven... |
|
2022
|
G/S
|
Assisting patients in enrolling in pharmaceutical reimbursement programs of others
Providing heal... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of oncological disorders, autoimmune disorders, inf... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of oncological
disorders, autoimmune disorders, in... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of oncological disorders, inflammatory disorder |
|
2021
|
G/S
|
Pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical pr... |
|
|
G/S
|
Providing medical information in the field of cancer treatment; provision of medical advisory ser... |
|
|
G/S
|
Providing medical information and advisory services regarding cancer. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of oncological disorders, inflammatory disorders |
|
|
Invention
|
Immunoconjugates with an intracellularly-cleavable linkage.
The present invention relates to the... |
|
|
Invention
|
Biomarkers for sacituzumab govitecan therapy.
The present invention relates to biomarkers of use... |
|
|
Invention
|
Biomarkers for sacituzumab govitecan therapy. The present invention relates to biomarkers of use ... |
|
|
Invention
|
Biomarkers for sacituzumab govitecan therapy. BRCA1, BRCA2, CHEK2, MSH2, MSH6, TP53, CDKN1A, BAG6... |
|
|
Invention
|
Neoadjuvant use of antibody-drug conjugates.
The present invention concerns improved methods and... |
|
|
G/S
|
Providing medical information and advisory services regarding cancer |
|
2020
|
G/S
|
Brochures, newsletters, pamphlets and patient care material
in the nature of booklets and hand-o... |
|
|
G/S
|
Providing a website to patients and healthcare professionals containing healthcare information re... |
|
|
Invention
|
Antibody-drug conjugates and uses thereof. The present invention relates to therapeutic immunocon... |
|
|
Invention
|
Biomarkers for antibody-drug conjugate monotherapy or combination therapy. The present invention ... |
|
|
Invention
|
Biomarkers for antibody-drug conjugate monotherapy or combination therapy.
The present invention... |
|
|
Invention
|
Antibody-sn-38 immunoconjugates with a cl2a linker.
The present invention concerns improved meth... |
|
2019
|
Invention
|
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cel... |
|
|
Invention
|
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-... |
|
|
Invention
|
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bru... |
|
|
Invention
|
Immunoconjugates with an intracellularly-cleavable linkage. The invention relates to therapeutic ... |
|
2018
|
G/S
|
Educational services, namely, providing ongoing information
to patients and healthcare providers... |
|
|
Invention
|
Immunoconjugates with an intracellularly-cleavable linkage. The present invention relates to ther... |
|
|
Invention
|
Efficacy of anti-hla-dr antibody drug conjugate immu-140 (hl243-cl2a-sn-38) in hla-dr positive ca... |
|
|
Invention
|
Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negat... |
|
|
Invention
|
Rs7 antibodies.
This invention relates to monovalent and multivalent, monospecific binding prote... |
|
|
Invention
|
Humanized anti-hla-dr antibodies.
The present invention concerns compositions and methods of use... |
|
|
Invention
|
Antibody-sn-38 immunoconjugates with a cl2a linker. The present invention concerns improved metho... |
|
|
G/S
|
Therapeutic pharmaceuticals, namely, antibody-drug
conjugates for the treatment of cancer. |
|
|
Invention
|
Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers. T... |
|
|
G/S
|
Educational services, namely, providing ongoing information to patients and healthcare providers ... |
|
|
Invention
|
Nucleic acids encoding chimeric and humanized anti-histone antibodies. The present invention conc... |
|
|
G/S
|
Therapeutic pharmaceuticals, namely, antibody-drug conjugates for the treatment of cancer |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharm... |
|
|
Invention
|
Subcutaneous administration of antibody-drug conjugates for cancer therapy. The present invention... |
|
2017
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
pharmaceutical preparations for the treatment of oncological disorders [, hematological disorders... |
|
|
Invention
|
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1. The present ... |
|
2015
|
G/S
|
Therapeutic pharmaceuticals, namely, antibodies and immunoconjugates for the treatment of cancer ... |
|
|
G/S
|
Therapeutic pharmaceuticals, namely, antibodies and
immunoconjugates for the treatment of cancer... |
|
2010
|
G/S
|
Pharmaceutical preparations for the treatment of cancer,
particularly monoclonal antibodies for ... |
|
1996
|
G/S
|
Reagents for use in science and industry. Reagents for use in medicine. |
|
|
G/S
|
Diagnostic kit comprising diagnostic reagents for the detection of infectious lesions. |
|
1994
|
G/S
|
Diagnostic kit comprising diagnostic reagents in the nature of antibodies or antibody fragments a... |
|
|
G/S
|
immunoassay kits for in vitro medical and laboratory diagnostic use |
|
|
G/S
|
immunodiagnostic kits comprising primarily immunological reagents |
|
1987
|
G/S
|
Immunodiagnostic kits comprising primarily immunological reagents. |
|
|
G/S
|
Immunoassays for circulating immune complexes to monitor and aid in the diagnosis of autoimmune d... |
